Bastien Nguyen

11PUBLICATIONS
122CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersHealth and ecological risk assessmentMolecular targetsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Oct 07, 2025
Genomic determinants of response and resistance to pirtobrutinib in relapsed/refractory chronic lymphocytic leukemia.

Jennifer R Brown, Bastien Nguyen, Sai Prasad Desikan

|Dec 18, 2024
Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial.

Kevin Kalinsky, Giampaolo Bianchini, Erika Hamilton

|Oct 08, 2024
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study.

Patrick Neven, Nicole Stahl, Maria Vidal

|Sep 06, 2024
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.

Komal L Jhaveri, Elgene Lim, Rinath Jeselsohn

|Jan 18, 2022
Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor.

Ping Chi, Li-Xuan Qin, Bastien Nguyen

|Oct 20, 2021
Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors.

Konrad H Stopsack, Subhiksha Nandakumar, Kanika Arora

Pageof 2

Frequent Collaborators

3 joint publications

Peter A Kaufman

3 joint publications

Erika P Hamilton

2 joint publications

Sandra P D'Angelo

2 joint publications

Konrad H Stopsack